Stockscreener 앱 받기
119.50
0.61%
0.72
시장 영업 전:
120.00
0.50
+0.42%
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Aigen Investment Management LP Purchases Shares of 4,663 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Investment Analysts’ Recent Ratings Updates for Axsome Therapeutics (AXSM) - Defense World
Lindbrook Capital LLC Lowers Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $167.36 - MarketBeat
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing - MSN
How to Take Advantage of moves in (AXSM) - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for Axsome Therapeutics (NASDAQ:AXSM) - Defense World
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals - MSN
Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 - MSN
Intra-Cellular deal, Axsome settlement drive neurological index recovery - BioWorld Online
Axsome Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Torray Investment Partners LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given New $160.00 Price Target at Robert W. Baird - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by New York State Common Retirement Fund - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by US Bancorp DE - MarketBeat
Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright maintains Axsome stock Buy rating, $200 target By Investing.com - Investing.com Canada
Axsome Therapeutics: Strategic Developments and Market Exclusivity Drive Buy Rating - TipRanks
H.C. Wainwright maintains Axsome stock Buy rating, $200 target - Investing.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of “Buy” by Analysts - Defense World
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Axsome settles patent litigation with Hikma over Sunosi By Investing.com - Investing.com Canada
Axsome Therapeutics gets FDA support to submit sNDA for its Alzheimer’s disease agitation treatment - MSN
Axsome resolves patent dispute with Hikma - MSN
Axsome Therapeutics Resolves Sunosi Patent Case With Hikma -March 05, 2025 at 08:08 am EST - Marketscreener.com
Axsome stock gains asHikma patent feud ends (AXSM:NASDAQ) - Seeking Alpha
Axsome Settles Patent Litigation With Hikma Related To SunosiQuick Facts - Nasdaq
Axsome settles patent litigation with Hikma over Sunosi - Investing.com India
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA - The Manila Times
Axsome Wins 16+ Years of Market Exclusivity for Sunosi in Patent Settlement - StockTitan
Robert W. Baird Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - Defense World
Axsome Therapeutics (NASDAQ:AXSM) Receives Buy Rating from Needham & Company LLC - Defense World
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $190.00 - MarketBeat
Axsome Therapeutics expects to submit sNDA for AXS-05 in Q3 - TipRanks
Axsome Therapeutics Receives FDA Indication in Support of Alzheimer's Drug Submission - Marketscreener.com
Axsome Therapeutics set for 3Q sNDA submission for AXS-05 - Investing.com
Axsome's Alzheimer's Agitation Drug Clears Critical FDA Hurdle After Triple Trial Success - StockTitan
New York State Common Retirement Fund Purchases 8,843 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
2.14%
2.83%
자본화:
|
볼륨(24시간):